Brief: Inhalerx Sats U.S. FDA Placed Temporary Suspension On Investigational New Drug Application
05/07/2024 10:50
July 5 (Reuters) - Inhalerx Ltd IRX.AX :
* U.S. FOOD AND DRUG ADMINISTRATION PLACED A TEMPORARY
SUSPENSION
ON ITS INVESTIGATIONAL NEW DRUG APPLICATION
* APPLICATION FOR A PHASE 1 CLINICAL TRIAL INVOLVING
IRX616A,
Further company coverage: IRX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nexalis Therapeutics
See all newsBrief: Nexalis Therapeutics Says Sean Williams Has Resigned As Non-Executive Chairman
Brief: Nexalis Therapeutics Signs Funding Partnership With Point8 Capital To Replace Existing Facility
Brief: Nexalis Therapeutics Seeks Trading Halt
Brief: Nexalis Therapeutics Says US Policy Market Advancement Supports SRX-25 TRD Treatment
Australia's Nexalis Therapeutics gains most in over 6 months on trial approval